Inventor · disambiguated record
Wei Deng
Also filed as: DENG WEI · DENG WEI QXI · LEE TAEKYU
38 granted patents·24 pending applications·1,571 citations·filing 2000–2025
98Inventor score
Files withTURNING POINT THERAPEUTICS INC19HUTCHISON MEDIPHARMA LTD8BRISTOL MYERS SQUIBB PHARMA CO7BRISTOL MYERS SQUIBB CO5NEWSOUTH INNOVATIONS PTY LTD2
Top patents by PatentIndex Score
62 records- 0198US7238690B2Substituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jul 3, 2007·127 cites·4 claims
- 0298US7183282B2Substituted heterocycle fused γ-carbolinesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2006·Granted Feb 27, 2007·145 cites·4 claims
- 0398US6552017B1Substituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2000·Granted Apr 22, 2003·208 cites·21 claims
- 0497USRE39680ESubstituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2006·Granted Jun 5, 2007·142 cites·21 claims
- 0597USRE39679ESubstituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2006·Granted Jun 5, 2007·129 cites·33 claims
- 0697US7081455B2Substituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Jul 25, 2006·115 cites·17 claims
- 0797US7071186B2Substituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2004·Granted Jul 4, 2006·121 cites·15 claims
- 0897US6713471B1Substituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2000·Granted Mar 30, 2004·172 cites·33 claims
- 0997US6548493B1Substituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2000·Granted Apr 15, 2003·179 cites·23 claims
- 1096US7592454B2Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonistsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Sep 22, 2009·62 cites·7 claims
- 1195US11155563B2Macrocyclic compounds and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2021·Granted Oct 26, 2021·3 cites·3 claims
- 1294US10745416B2Macrocyclic compounds for treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Aug 18, 2020·4 cites·29 claims
- 1394US7109339B2Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonistsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Sep 19, 2006·88 cites·5 claims
- 1492US11142533B2Macrocycles for use in treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2021·Granted Oct 12, 2021·2 cites·3 claims
- 1592US10316044B2Chiral diaryl macrocycles as modulators of protein kinasesTP THERAPEUTICS INC·Filed 2016·Granted Jun 11, 2019·18 cites·22 claims
- 1691US11981684B2Macrocyclic compounds and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2022·Granted May 14, 2024·1 cites·20 claims
- 1791US11286264B2Macrocyclic compounds and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2018·Granted Mar 29, 2022·4 cites·21 claims
- 1887US9346810B2Pyrrolopyrimidine compounds and uses thereofSU WEI-GUO·Filed 2011·Granted May 24, 2016·11 cites·6 claims
- 1985US11452725B2Chiral diaryl macrocycles and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·1 cites·20 claims
- 2085US7851637B2Compounds and methods for inhibiting the interaction of BCL proteins with binding partnersINFINITY PHARMACEUTICALS INC·Filed 2005·Granted Dec 14, 2010·13 cites·17 claims
- 2184US11634433B2Macrocycles for use in treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Apr 25, 2023·1 cites·17 claims
- 2282US6525044B2Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein productionBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Feb 25, 2003·14 cites·18 claims
- 2379US12310968B2Chiral diaryl macrocycles and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2022·Granted May 27, 2025·0 cites·27 claims
- 2479US10208066B2Imidazopyridazine compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2015·Granted Feb 19, 2019·4 cites·16 claims
- 2579US8916697B2Nucleic acid complexesPURDUE RESEARCH FOUNDATION·Filed 2013·Granted Dec 23, 2014·2 cites·22 claims
- 2677US10052330B2Substituted pyrido[3,4-b]pyrazines as Syk inhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2016·Granted Aug 21, 2018·2 cites·34 claims
- 2777US2025375451A1Chiral diaryl macrocycles and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2875US2023322806A1Macrocycles for use in treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2974US9434726B2Substituted pyrido[3,4-b]pyrazines as Syk inhibitorsSU WEI-GUO·Filed 2012·Granted Sep 6, 2016·2 cites·28 claims
- 3072US2022306652A1Macrocyclic compounds for treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3171US11286265B2Macrocyclic compounds for treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Mar 29, 2022·0 cites·15 claims
- 3271US10111875B2Pyrrolopyrimidine compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2016·Granted Oct 30, 2018·1 cites·23 claims
- 3369US2024033266A1Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3467US2023398119A1Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3564US9526802B2Nucleic acid complexesPURDUE RESEARCH FOUNDATION·Filed 2014·Granted Dec 27, 2016·0 cites·22 claims
- 3663US11654145B2Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2020·Granted May 23, 2023·0 cites·30 claims
- 3762US11666574B2Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Jun 6, 2023·0 cites·17 claims
- 3857US10369153B2Pyrrolopyrimidine compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2018·Granted Aug 6, 2019·0 cites·6 claims
- 3955US2004034015A1Substituted heterocycle fused gamma-carbolinesFiled 2003·Application pending·0 cites
- 4055US2024285658A1Pharmaceutical assembly comprising tobramycin inhalation solution and use thereofJOINCARE PHARMACEUTICAL GROUP IND CO LTD·Filed 2022·Application pending·0 cites
- 4154US11008337B2Chiral diaryl macrocycles as modulators of protein kinasesTURNING POINT THERAPEUTICS INC·Filed 2019·Granted May 18, 2021·0 cites·22 claims
- 4254US10611777B2Imidazopyridazine compounds and their useHUTCHISON MEDIPHARMA LTD·Filed 2018·Granted Apr 7, 2020·0 cites·19 claims
- 4354US2024002388A1Pyrimidinone compounds and uses thereofHUTCHISON MEDIPHARMA LTD·Filed 2021·Application pending·0 cites
- 4454US2004127482A1Substituted heterocycle fused gamma-carbolinesFiled 2003·Application pending·0 cites
- 4553US2018325901A1Chiral diaryl macrocycles and uses thereofTP THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4651US2024140931A1Tricyclic compounds and uses thereofHUTCHMED LTD·Filed 2022·Application pending·0 cites
- 4751US2017152258A9Substituted Pyridopyrazines as Syk InhibitorsHUTCHISON MEDIPHARMA LTD·Filed 2013·Application pending·0 cites
- 4850US2023031980A1Methods and compositions for treating and diagnosing a sage1-related conditionSHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE·Filed 2020·Application pending·0 cites
- 4949US2023219986A1Novel aminopyrimidine egfr inhibitorQILU PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 5049US2024034743A9Tricyclic compounds as egfr inhibitorsQILU PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Wei Deng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →